Novanox may be available in the countries listed below.
Ingredient matches for Novanox
Nitrazepam
Nitrazepam is reported as an ingredient of Novanox in the following countries:
- Germany
International Drug Name Search
Tuesday 27 October 2009
Monday 19 October 2009
Noracin
Noracin may be available in the countries listed below.
Ingredient matches for Noracin
Norfloxacin
Norfloxacin is reported as an ingredient of Noracin in the following countries:
- Bosnia & Herzegowina
- Tunisia
International Drug Name Search
Friday 16 October 2009
Desossicortone
Desossicortone may be available in the countries listed below.
Ingredient matches for Desossicortone
Desoxycortone
Desossicortone (DCIT) is also known as Desoxycortone (Rec.INN)
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Click for further information on drug naming conventions and International Nonproprietary Names.
Tuesday 13 October 2009
Emericid
Emericid may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ingredient matches for Emericid
Sulfadimethoxine
Sulfadimethoxine is reported as an ingredient of Emericid in the following countries:
- France
International Drug Name Search
Wednesday 7 October 2009
Dexacidin
Generic Name: neomycin, polymyxin B, and dexamethasone ophthalmic (NEE oh MYE sin, POL ee MIX in DEX a METH a sone off THAL mik)
Brand Names: Maxitrol, Ocu-Trol, Poly-Dex
What is neomycin, polymyxin B and dexamethasone ophthalmic?
Neomycin and polymyxin B are antibiotics. They are used to treat bacterial infections.
Dexamethasone is a steroid. It is used to treat the swelling associated with bacterial infections of the eye.
Neomycin, polymyxin B and dexamethasone ophthalmic is used to treat bacterial infections of the eyes.
Neomycin, polymyxin B and dexamethasone ophthalmic may also be used for purposes other than those listed in this medication guide.
What is the most important information I should know about neomycin, polymyxin B and dexamethasone ophthalmic?
Contact your doctor if your symptoms begin to get worse or if you do not see any improvement in your condition after a few days.
Do not touch the dropper or tube opening to any surface, including your eyes or hands. The dropper or tube opening is sterile. If it becomes contaminated, it could cause an infection in your eye.
Apply light pressure to the inside corner of your eye (near your nose) after each drop to prevent the fluid from draining down your tear duct.
Who should not use neomycin, polymyxin B and dexamethasone ophthalmic?
Do not use neomycin, polymyxin B and dexamethasone ophthalmic if you have a viral or fungal infection in your eye. It is used to treat infections caused by bacteria only. It is not known whether neomycin, polymyxin B and dexamethasone ophthalmic will harm an unborn baby. Do not use this medication without first talking to your doctor if you are pregnant. It is not known whether neomycin, polymyxin B and dexamethasone ophthalmic passes into breast milk. Do not use this medication without first talking to your doctor if you are breast-feeding a baby.
How should I use neomycin, polymyxin B and dexamethasone ophthalmic?
Use neomycin, polymyxin B and dexamethasone eyedrops or ointment exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.
Wash your hands before and after using your eyedrops or ointment.
To apply the eyedrops:
Shake the drops gently to be sure the medicine is well mixed. Tilt your head back slightly and pull down on your lower eyelid. Position the dropper above your eye. Look up and away from the dropper. Squeeze out a drop and close your eye. Apply gentle pressure to the inside corner of your eye (near your nose) for about 1 minute to prevent the liquid from draining down your tear duct. If you are using more than one drop in the same eye or drops in both eyes, repeat the process with about 5 minutes between drops.
To apply the ointment:
Hold the tube in your hand for a few minutes to warm it up so that the ointment comes out easily. Tilt your head back slightly and pull down gently on your lower eyelid. Apply a thin film of the ointment into your lower eyelid. Close your eye and roll your eyeball around in all directions for 1 to 2 minutes. If you are applying another eye medication, allow at least 10 minutes before your next application.
Do not touch the dropper or tube opening to any surface, including your eyes or hands. The dropper or tube opening is sterile. If it becomes contaminated, it could cause an infection in your eye.
Never use any eyedrop that is discolored or has particles in it.
Store neomycin, polymyxin B and dexamethasone ophthalmic at room temperature away from moisture and heat. Keep the bottle or tube properly capped.
What happens if I miss a dose?
Apply the missed dose as soon as you remember. However, if it is almost time for your next regularly scheduled dose, skip the missed dose and apply the next one as directed. Do not use a double dose of this medication.
What happens if I overdose?
An overdose of this medication is unlikely to occur. If you do suspect an overdose, wash the eye with water and call an emergency room or poison control center near you. If the drops or ointment have been ingested, drink plenty of fluid and call an emergency center for advice.
What should I avoid while using neomycin, polymyxin B and dexamethasone ophthalmic?
Do not touch the dropper or tube opening to any surface, including your eyes or hands. The dropper or tube opening is sterile. If it becomes contaminated, it could cause an infection in your eye. Use caution when driving, operating machinery, or performing other hazardous activities. Neomycin, polymyxin B and dexamethasone ophthalmic may cause blurred vision. If you experience blurred vision, avoid these activities.
Use caution with contact lenses. Wear them only if your doctor approves. After applying this medication, wait at least 15 minutes before inserting contact lenses.
Avoid other eye medications unless your doctor approves.
Neomycin, polymyxin B and dexamethasone ophthalmic side effects
Serious side effects are not expected with this medication.
Some burning, stinging, irritation, itching, redness, blurred vision, eyelid itching, eyelid swelling, or sensitivity to light may occur.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect neomycin, polymyxin B and dexamethasone ophthalmic?
Avoid other eye medications unless they are approved by your doctor.
Before using this medication, tell your doctor if you are taking an oral steroid medication such as prednisone (Deltasone, Orasone, others).
Drugs other than those listed here may also interact with neomycin, polymyxin B and dexamethasone ophthalmic. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.
More Dexacidin resources
- Dexacidin Side Effects (in more detail)
- Dexacidin Use in Pregnancy & Breastfeeding
- Dexacidin Drug Interactions
- Dexacidin Support Group
- 0 Reviews for Dexacidin - Add your own review/rating
- Maxitrol Drops MedFacts Consumer Leaflet (Wolters Kluwer)
Compare Dexacidin with other medications
- Blepharitis
- Conjunctivitis, Bacterial
- Keratitis
- Keratoconjunctivitis
- Uveitis
Where can I get more information?
- Your pharmacist has additional information about neomycin, polymyxin B and dexamethasone written for health professionals that you may read.
See also: Dexacidin side effects (in more detail)
Hi Tet
Hi Tet may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ingredient matches for Hi Tet
Oxytetracycline
Oxytetracycline dihydrate (a derivative of Oxytetracycline) is reported as an ingredient of Hi Tet in the following countries:
- South Africa
Oxytetracycline hydrochloride (a derivative of Oxytetracycline) is reported as an ingredient of Hi Tet in the following countries:
- South Africa
International Drug Name Search
Sunday 4 October 2009
Desonide Cream
Desonide Cream 0.05%
Desonide Ointment 0.05%
Rx only
FOR EXTERNAL USE ONLY. FOR DERMATOLOGIC USE ONLY.
NOT FOR OPHTHALMIC USE.
Desonide Cream Description
Desonide Cream 0.05% and Ointment 0.05% contain desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11β, 16α)) a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
Chemically, desonide is C24H32O6. It has the following structural formula:
Desonide has the molecular weight of 416.51. It is a white to off white odorless powder which is soluble in methanol and practically insoluble in water.
Each gram of Desonide Cream contains 0.5 mg of desonide in a compatible vehicle buffered to the pH range of normal skin. It contains aluminum acetate basic, cetearyl alcohol/SLS/SCS, glycerin, mineral oil, purified water, white petrolatum and white wax. It is preserved with methylparaben.
Each gram of Desonide Ointment contains 0.5 mg of desonide in an ointment base consisting of mineral oil and white petrolatum.
Desonide Cream - Clinical Pharmacology
Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Pharmacokinetics
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Studies performed with Desonide Cream and ointment indicate that they are in the low to medium range of potency as compared with other topical corticosteroids.
Indications and Usage for Desonide Cream
Desonide Cream and ointment are low to medium potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Contraindications
Desonide Cream and ointment are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Precautions
General
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.
Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA axis suppression.
If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.
Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See PRECAUTIONS - Pediatric Use)
If irritation develops, Desonide Cream or ointment should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.
If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Desonide Cream or ointment should be discontinued until the infection has been adequately controlled.
Information for patients
Patients using topical corticosteroids should receive the following information and instructions:
- This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
- This medication should not be used for any disorder other than that for which it was prescribed.
- The treated skin area should not be bandaged or otherwise covered or wrapped so as to be occlusive unless directed by the physician.
- Patients should report to their physician any signs of local adverse reactions.
Laboratory tests
The following tests may be helpful in evaluating patients for HPA axis suppression:
- ACTH stimulation test
- A.M. plasma cortisol test
- Urinary free cortisol test
Carcinogenesis, mutagenesis, and impairment of fertility
Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on reproduction with the use of Desonide Cream or ointment.
Pregnancy
Teratogenic effects
Pregnancy category C
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproduction studies have not been conducted with Desonide Cream or ointment. It is also not known whether Desonide Cream or ointment can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Desonide Cream and ointment should be given to a pregnant woman only if clearly needed.
Nursing mothers
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Desonide Cream or ointment is administered to a nursing woman.
Pediatric use
Safety and effectiveness in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids. They are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children.
HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
Adverse Reactions
In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide was approximately 8%. These were: stinging and burning, approximately 3%, irritation, contact dermatitis, condition worsened, peeling of skin, itching, intense transient erythema, and dryness/scaliness, each less than 2%.
The following additional local adverse reactions have been reported infrequently with other topical corticosteroids, and they may occur more frequently with the use of occlusive dressings especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria.
Overdosage
Topically applied Desonide Cream and ointment can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS)
Desonide Cream Dosage and Administration
Desonide Cream or ointment should be applied to the affected areas as a thin film two or three times daily depending on the severity of the condition.
As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
Desonide Cream and ointment should not be used with occlusive dressings.
How is Desonide Cream Supplied
Desonide Cream 0.05% is supplied in 60 g (NDC 23589-052-60) tubes.
Desonide Ointment 0.05% is supplied in 60 g (NDC 23589-053-60) tubes.
Storage conditions
Store at 20°- 25°C (68°- 77°F). [see USP Controlled Room Temperature].
Protect from freezing.
Manufactured by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1
Manufactured for: TIBER LABORATORIES, Suwanee, GA 30024
Issued: April, 2010
REV. 04/10 052/053-10
PK-6513-0
95
PRINCIPAL DISPLAY PANEL - 60 g Tube Carton
NDC 23589-052-60
Desonide
Cream 0.05%
FOR EXTERNAL USE ONLY.
NOT FOR OPHTHALMIC USE.
Keep this and all medications out of the reach of children.
TIBER
LABORATORIES
60 g
Rx only
| DESONIDE desonide cream | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA073548 | 06/30/1992 | 06/30/2012 |
| Labeler - Tiber Laboratories, LLC (008913939) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Taro Pharmaceuticals Inc. | 206263295 | MANUFACTURE | |
More Desonide Cream resources
- Desonide Cream Side Effects (in more detail)
- Desonide Cream Use in Pregnancy & Breastfeeding
- Desonide Cream Drug Interactions
- Desonide Cream Support Group
- 17 Reviews for Desonide - Add your own review/rating
Compare Desonide Cream with other medications
- Atopic Dermatitis
- Dermatitis
- Eczema
- Psoriasis
Subscribe to:
Posts (Atom)